CUSIP: 50107A104
Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock
-
Total 13F shares
-
31,591,332
-
Share change
-
-804,940
-
Total reported value
-
$54,317,965
-
Price per share
-
$1.72
-
Number of holders
-
80
-
Value change
-
-$1,182,464
-
Number of buys
-
32
-
Number of sells
-
49
Security key
50107A104
Report period
Q2 2023
Institutions
80
Top holders
10
Reporting periods
Holder history for CUSIP 50107A104
Recent filing periods:
Top shareholders of KRON - Kronos Bio, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
No top shareholder records were found across 13F, 13D/G, and Forms 3/4/5 for this issuer.
Institutional Holders of Kronos Bio, Inc. - Common Stock (KRON) as of Q2 2023
As of 30 Jun 2023,
Kronos Bio, Inc. - Common Stock (KRON) was held by
80 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
31,591,332 shares.
The largest 10 holders included
Omega Fund Management, LLC, BVF INC/IL, Vida Ventures Advisors, LLC, PERCEPTIVE ADVISORS LLC, PARTNERS CAPITAL INVESTMENT GROUP, LLP, VANGUARD GROUP INC, Artal Group S.A., Nextech Invest Ltd., Alphabet Inc., and BlackRock Inc..
This page lists
80
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
Compare Q2 2023 vs Q1 2023 Across Filers
| Investor |
Q1 2023 Shares |
Q2 2023 Shares |
Share Diff |
Share Chg % |
Q1 2023 Value $ |
Q2 2023 Value $ |
Value Diff $ |
Value Chg % |
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.